271 related articles for article (PubMed ID: 6380076)
1. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
Victor A; Lithell H; Selinus I; Vessby B
Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
[TBL] [Abstract][Full Text] [Related]
3. [Contraception in the hypertensive woman using a vaginal ring delivering estradiol and norgestrel].
Elkik F; Basdevant A; Corvol P
Arch Mal Coeur Vaiss; 1985 Oct; 78(11):1737-9. PubMed ID: 3938250
[TBL] [Abstract][Full Text] [Related]
4. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
[TBL] [Abstract][Full Text] [Related]
5. Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel.
Larsson-Cohn U; Wallentin L; Zador G
Horm Metab Res; 1979 Jul; 11(7):437-40. PubMed ID: 225252
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
[TBL] [Abstract][Full Text] [Related]
7. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
9. Subdermal norethindrone pellets -- a method for contraception?
Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
[TBL] [Abstract][Full Text] [Related]
10. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
Hirvonen E; Mälkönen M; Manninen V
N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
[TBL] [Abstract][Full Text] [Related]
11. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
Ylikorkala O; Lim P; Caubel P
Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
[TBL] [Abstract][Full Text] [Related]
12. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.
Song S; Chen JK; Lu CH; Yang PJ; Yang QY; Fan BC; He ML; Gui YL; Li LM; Fotherby K
Contraception; 1993 Jun; 47(6):527-37. PubMed ID: 8334889
[TBL] [Abstract][Full Text] [Related]
13. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
[TBL] [Abstract][Full Text] [Related]
15. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
[TBL] [Abstract][Full Text] [Related]
16. [Plasma concentrations of LH and of sex steroids during the normal menstrual cycle and during contraceptive treatment].
Bayard F; Louvet JP; Moatti JP; Smilovici W; Duguet L; Boulard C
J Gynecol Obstet Biol Reprod (Paris); 1975; 4(7):915-26. PubMed ID: 767402
[TBL] [Abstract][Full Text] [Related]
17. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
Fraser IS; Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Tsong YY; Sivin I
Contraception; 2005 Jul; 72(1):40-5. PubMed ID: 15964291
[TBL] [Abstract][Full Text] [Related]
18. Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins.
Ahrén T; Victor A; Lithell H; Vessby B; Jackanicz TM; Johansson ED
Contraception; 1983 Oct; 28(4):315-27. PubMed ID: 6667620
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
Gynecol Endocrinol; 2002 Apr; 16(2):155-62. PubMed ID: 12012627
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
Nash AL; Cornish EJ; Hain R
Med J Aust; 1979 Sep; 2(6):277-81. PubMed ID: 230411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
